Research
Hormonal
GLP-1 receptor agonists (e.g., liraglutide, semaglutide) and SGLT2 inhibitors provide cardiovascular and renal benefits independent of glycemic control, with GLP-1 RAs being preferred for obesity/T2D and SGLT2 inhibitors for T2D with heart failure.
If you have T2D and obesity, ask your doctor about GLP-1 agonists (like Semaglutide or Liraglutide). They help with weight loss and protect your heart and kidneys, even if your blood sugar is already controlled. If you also have heart failure, SGLT2 inhibitors might be better.
StrongSupportsVERY_HIGH confidence
In T2D and obesity, GLP-1 RA should be used as a preferred glucose-lowering treatment, whereas in patients with T2D, obesity and heart failure in cardiovascular disease SGLT2 inhibitors should be prioritized.
Why this rating
Based on multiple large-scale Cardiovascular Outcome Trials (EMPA-REG, LEADER) and meta-analyses.
Source
Management of obesity in the times of climate change and COVID-19: an interdisciplinary expert consensus report
Ewa Płaczkiewicz‐Jankowska et al. · Polskie Archiwum Medycyny Wewnętrznej · 2022
clinical_guidelineCited 8×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →